RESprotect GmbH
Records under this name other than patents RESprotect GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 5 of 5 · Back to RESprotect GmbH
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,492,537 | Nucleosides for suppressing or reducing the development of resistance in cytostatic therapy Lapsed on the fee record Ended Jul 23, 2021 · From the USPTO record | Lapsed on the fee record | Ended Jul 23, 2021 | From the USPTO record |
| US 9,181,199 | Uracil derivatives and use thereof Lapsed on the fee record Ended Nov 10, 2019 · From the USPTO record | Lapsed on the fee record | Ended Nov 10, 2019 | From the USPTO record |
| US 7,713,948 | Use of 5-substituted nucleosides for reinforcing the apoptotic effect of cytostatic drugs Lapsed on the fee record Ended May 11, 2018 · From the USPTO record | Lapsed on the fee record | Ended May 11, 2018 | From the USPTO record |
| US 6,589,941 | Utilization of 5′ substituted nucleosides for resistance formation in cytoclastic treatment, and drug containing these nucleosides, polymers, methods of use and compositions Term ended Term ended Jan 31, 2016 · From the USPTO record | Term ended | Term ended Jan 31, 2016 | From the USPTO record |
| US 7,122,528 | Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases Lapsed on the fee record Ended Oct 17, 2010 · From the USPTO record | Lapsed on the fee record | Ended Oct 17, 2010 | From the USPTO record |